2020
DOI: 10.3390/pharmacy8020059
|View full text |Cite
|
Sign up to set email alerts
|

Contrasting PTH Response of Denosumab Use in Dialysis Patients: A Report of 2 Cases

Abstract: A common complication of end-stage renal disease (ESRD) is mineral and bone disorder. Yet, many anti-osteoporotic drugs are contraindicated in ESRD patients. Denosumab, a monoclonal antibody, does not require renal dose adjustment. However, its use is uncertain due to a lack of safety and efficacy of data in this population. Two hemodialysis patient cases of contrasting responses in parathyroid hormone (PTH) after denosumab administration were observed. Patient 1, a 62-years-old male received denosumab 60 mg a… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 17 publications
0
1
0
Order By: Relevance
“…Despite efforts to mitigate hypocalcemia [ 3 , 17 ], the significant increase in PTH post-denosumab administration in our study suggests that mechanisms beyond hypocalcemia triggered this increase. As a mechanism to explain this, the possibility of an osteoanabolic effect of PTH due to a decrease in cortical porosity in the early stages of denosumab administration has been suggested [ 27 , 28 ], but the exact mechanism is not yet known.…”
Section: Discussionmentioning
confidence: 99%
“…Despite efforts to mitigate hypocalcemia [ 3 , 17 ], the significant increase in PTH post-denosumab administration in our study suggests that mechanisms beyond hypocalcemia triggered this increase. As a mechanism to explain this, the possibility of an osteoanabolic effect of PTH due to a decrease in cortical porosity in the early stages of denosumab administration has been suggested [ 27 , 28 ], but the exact mechanism is not yet known.…”
Section: Discussionmentioning
confidence: 99%